Loading...
Market
Will Massive Bio and Foundation Medicine increase clinical trial enrollment rates by 20% by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Massive Bio or Foundation Medicine, industry reports, or scientific publications
Story
Massive Bio Partners with Foundation Medicine to Improve Cancer Clinical Trials at ESMO24
Sep 13, 2024, 12:09 PM
Biotech company Massive Bio has announced a partnership with Foundation Medicine to enhance clinical trial recruitment and enrollment, focusing on precision cancer care. The collaboration aims to address the low enrollment rates in cancer clinical trials by leveraging AI and genomic profiling. This partnership, highlighted at the ESMO24 conference, is seen as a pivotal step in developing solutions to the cancer clinical trial enrollment paradox, potentially allowing more patients to access advanced treatments.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%